FDA approves generic bronchial mucolytic by InnoPharma

09/20/2012 | Pharmaceutical Business Review Online

InnoPharma's abbreviated new-drug application for bronchial mucolytic Acetylcysteine Solution, USP, received FDA approval for oral administration or inhalation. Under a contract, Fresenius Kabi USA will market, distribute and sell the generic drug. The treatment is indicated for inspissated, viscid or abnormal mucous secretion in patients with lung diseases including acute or chronic bronchopulmonary disease.

View Full Article in:

Pharmaceutical Business Review Online

Published in Briefs: